CD4+ T Cells Elicit Host Immune Responses to MHC Class II− Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells
Open Access
- 15 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 184 (10) , 5654-5662
Abstract
T cell adoptive transfer strategies that have produced clinical remissions against specific tumors have so far produced disappointing results against ovarian cancer. Recent evidence suggests that adoptively transferred CD4+ T cells can trigger endogenous immune responses in particular patients with ovarian cancer through unknown mechanisms. However, conflicting reports suggest that ovarian cancer-infiltrating CD4+ T cells are associated with negative outcomes. In this study, we elucidate the phenotypic attributes that enable polyclonal CD4+ T cells briefly primed against tumor Ags to induce therapeutically relevant endogenous antitumor immune responses. Our results unveil a therapeutic mechanism whereby tumor-primed CD4+ T cells transferred into ovarian cancer-bearing mice secrete high levels of CCL5, which recruits endogenous CCR5+ dendritic cells to tumor locations and activate them through CD40–CD40L interactions. These newly matured dendritic cells are then able to prime tumor-specific endogenous CD8+ T cells, which mediate long-term protection. Correspondingly, administration of tumor-primed CD4+ T cells significantly delayed progression of MHC class II− ovarian cancers, similarly to CD8+ T cells only, and directly activated wild-type but not CD40-deficient dendritic cells recruited to the tumor microenvironment. Our results unveil a CCL5- and CD40L-dependent mechanism of transferring immunity from exogenously activated CD4+ T cells to tumor-exposed host cells, resulting in sustained antitumor effects. Our data provide a mechanistic rationale for incorporating tumor-reactive CD4+ T cells in adoptive cell transfer immunotherapies against ovarian cancer and underscore the importance of optimizing immunotherapeutic strategies for the specific microenvironment of individual tumors.Keywords
This publication has 36 references indexed in Scilit:
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survivalClinical Immunology, 2009
- Engineering lymphocyte subsets: tools, trials and tribulationsNature Reviews Immunology, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Adoptive immunotherapy of cancer using CD4+ T cellsCurrent Opinion in Immunology, 2009
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Adoptive Cell Transfer TherapySeminars in Oncology, 2007
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006